Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108081
Title:
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.
Authors:
Thatcher, Nick; Sharma, H; Harrison, R; Smith, A; Zaki, A; McAuliffe, C A; Crowther, Derek; Fox, Brian W
Abstract:
The blood clearances of three platinum compounds, cis-dichlorodiammine platinum II (DDP), cis, trans-dichloro-dihydroxy-bis-(isopropylamine) platinum IV (CHIP), and cis-dichloro-bis-cyclopropylamine platinum II (CP), were determined in nine patients with malignant disease. The complexes were prepared using radioactive platinum (191Pt and 193Pt). A 10-mu Ci dose of each complex, containing the equivalent of 1-2 mg elemental platinum, was injected IV into groups of three patients. Serial blood and urine samples were collected over 72 h. No obvious difference was found between the three complexes for blood clearance, median t1/2a being 16.8 (range 11.2-23.5) min and median t1/2 beta 89 (range 63.7-127) h. The urinary excretion was greatest for CHIP, 60% of injected dose as against 42.6% for CP and 38.8% for DDP. Differences in renal excretion of DDP analogues could indicate potentially less nephrotoxic agents. The use of radioactive Pt will allow in vivo dynamic imaging of the distribution of platinum compounds in areas of interest.
Affiliation:
Department of Medical Oncology, Christie Hospital, Wilmslow Road, M20 9BX Manchester.
Citation:
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. 1982, 9 (1):13-6 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1982
URI:
http://hdl.handle.net/10541/108081
DOI:
10.1007/BF00296754
PubMed ID:
6890414
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorSharma, Hen
dc.contributor.authorHarrison, Ren
dc.contributor.authorSmith, Aen
dc.contributor.authorZaki, Aen
dc.contributor.authorMcAuliffe, C Aen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorFox, Brian Wen
dc.date.accessioned2010-07-21T14:06:32Z-
dc.date.available2010-07-21T14:06:32Z-
dc.date.issued1982-
dc.identifier.citationBlood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. 1982, 9 (1):13-6 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid6890414-
dc.identifier.doi10.1007/BF00296754-
dc.identifier.urihttp://hdl.handle.net/10541/108081-
dc.description.abstractThe blood clearances of three platinum compounds, cis-dichlorodiammine platinum II (DDP), cis, trans-dichloro-dihydroxy-bis-(isopropylamine) platinum IV (CHIP), and cis-dichloro-bis-cyclopropylamine platinum II (CP), were determined in nine patients with malignant disease. The complexes were prepared using radioactive platinum (191Pt and 193Pt). A 10-mu Ci dose of each complex, containing the equivalent of 1-2 mg elemental platinum, was injected IV into groups of three patients. Serial blood and urine samples were collected over 72 h. No obvious difference was found between the three complexes for blood clearance, median t1/2a being 16.8 (range 11.2-23.5) min and median t1/2 beta 89 (range 63.7-127) h. The urinary excretion was greatest for CHIP, 60% of injected dose as against 42.6% for CP and 38.8% for DDP. Differences in renal excretion of DDP analogues could indicate potentially less nephrotoxic agents. The use of radioactive Pt will allow in vivo dynamic imaging of the distribution of platinum compounds in areas of interest.en
dc.language.isoenen
dc.subjectCanceren
dc.subjectCancer Metastasisen
dc.subject.meshAged-
dc.subject.meshCisplatin-
dc.subject.meshFemale-
dc.subject.meshHalf-Life-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshNeoplasms-
dc.subject.meshOrganoplatinum Compounds-
dc.subject.meshPlatinum-
dc.subject.meshRadioisotopes-
dc.subject.meshSolubility-
dc.subject.meshTime Factors-
dc.titleBlood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Wilmslow Road, M20 9BX Manchester.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.